Arcus Biosciences RCUS Access rights — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's access rights — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's access rights — total revenues?
- Arcus Biosciences (RCUS) reported access rights — total revenues of $3M in Q1 2026.
- How has Arcus Biosciences's access rights — total revenues changed year-over-year?
- Arcus Biosciences's access rights — total revenues decreased by 50.0% year-over-year, from $6M to $3M.
- What is the long-term trend for Arcus Biosciences's access rights — total revenues?
- Over 2 years (2022 to 2025), Arcus Biosciences's access rights — total revenues has grown at a -28.2% compound annual growth rate (CAGR), from $33M to $17M.
- What does access rights — total revenues mean?
- This metric represents the total revenue recognized from granting access rights, licenses, or intellectual property usage to third-party partners. It reflects the financial value generated from the commercialization or strategic out-licensing of proprietary technology and research assets. Monitoring this figure helps investors assess the company's ability to monetize its R&D pipeline through collaborative agreements.